These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32511754)

  • 41. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preliminary Asian experience of using perampanel in clinical practice.
    Chiang HI; Lim SN; Hsieh HY; Cheng MY; Chang CW; Johnny Tseng WE; Li HT; Lin CY; Wu T
    Biomed J; 2017 Dec; 40(6):347-354. PubMed ID: 29433838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accidental injuries in patients with generalized tonic-clonic seizures. A multicenter, observational, cross-sectional study (QUIN-GTC study).
    Salas-Puig X; Iniesta M; Abraira L; Puig J;
    Epilepsy Behav; 2019 Mar; 92():135-139. PubMed ID: 30658321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
    Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
    J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
    Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
    Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study.
    Wheless J; Wechsler RT; Penovich P; Segal E; Chez M; Coppola A; Datta A; D'Souza W; Najm I; Cappucci S; Sainz-Fuertes R; Villanueva V
    Epilepsy Behav; 2023 Oct; 147():109369. PubMed ID: 37619459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Malhotra M; Patten A; Kaneko S
    Epilepsia Open; 2024 Apr; 9(2):501-512. PubMed ID: 37867420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy.
    Gil-Nagel A; Burd S; Toledo M; Sander JW; Lebedeva A; Patten A; Laurenza A;
    Seizure; 2018 Jan; 54():61-66. PubMed ID: 29288911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes.
    Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ
    Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability.
    Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A
    Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.
    Yamamoto T; Gil-Nagel A; Wheless JW; Kim JH; Wechsler RT
    Epilepsy Behav; 2022 Nov; 136():108885. PubMed ID: 36150304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of perampanel by etiology in Japanese patients with epilepsy-subpopulation analysis of a prospective post-marketing observational study.
    Nakai M; Nishimoto S; Higashibeppu Y; Inoue Y
    Epilepsia Open; 2024 Oct; 9(5):1772-1782. PubMed ID: 38963336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study.
    D'Souza W; Alsaadi T; Montoya J; Carreño M; Di Bonaventura C; Mohanraj R; Yamamoto T; McMurray R; Shastri O; Villanueva V;
    Seizure; 2022 Aug; 100():56-66. PubMed ID: 35777333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic-clonic seizures.
    Kerr WT; Ngo LY; Zhu L; Patten A; Cheng JY; Reddy AS; French JA
    Epilepsia; 2024 Aug; 65(8):2412-2422. PubMed ID: 38864472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of mono- and add-on perampanel in pediatric patients with epilepsy: Experience from a single-center retrospective study.
    Li Y; Guo HL; Hu YH; Wang J; Zhang YY; Huang J; Xu J; Chen J; Lu XP; Chen F
    Epilepsia Open; 2024 Feb; 9(1):268-277. PubMed ID: 37943144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
    Trinka E; Tsong W; Toupin S; Patten A; Wilson K; Isojarvi J; James D
    Epilepsy Res; 2020 Oct; 166():106403. PubMed ID: 32673969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjunctive Perampanel in Older Patients With Epilepsy: A Multicenter Study of Clinical Practice.
    Lattanzi S; Cagnetti C; Foschi N; Ciuffini R; Osanni E; Chiesa V; Dainese F; Dono F; Canevini MP; Evangelista G; Paladin F; Bartolini E; Ranzato F; Nilo A; Pauletto G; Marino D; Rosati E; Bonanni P; Marrelli A
    Drugs Aging; 2021 Jul; 38(7):603-610. PubMed ID: 34075567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.